Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
4(44%)
Results Posted
20%(1 trials)

Phase Distribution

Ph phase_1
1
11%
Ph not_applicable
3
33%
Ph phase_4
2
22%
Ph phase_2
3
33%

Phase Distribution

1

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
3(33.3%)
Phase 4Post-market surveillance
2(22.2%)
N/ANon-phased studies
3(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

9

all time

Status Distribution
Active(4)
Completed(5)

Detailed Status

Completed5
Recruiting4

Development Timeline

Analytics

Development Status

Total Trials
9
Active
4
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (11.1%)
Phase 23 (33.3%)
Phase 42 (22.2%)
N/A3 (33.3%)

Trials by Status

completed556%
recruiting444%

Recent Activity

Clinical Trials (9)

Drug Details

Intervention Type
DRUG
Total Trials
9